Bio-Rad Laboratories () BLOOD VIRUS DIVISION



Geenius™ HIV 1/2 Supplemental Assay

2012 National Summit. HIV Diagnosis and Testing – Routine and Expanded Testing Washington D.C.; November 27, 2012



Christopher Bentsen, Bio-Rad Laboratories, Redmond, WA

Geenius HIV-1/2 Supplemental Assay






Geenius HIV-1/2 Cassette Geenius Reader Computer with Geenius software

2012 National Summit on HIV and Viral Hepatitis Diagnosis, Prevention and Access to Care. November 27, 2012






The Geenius[™] HIV-1/2 Lines

2012 National Summit on HIV and Viral Hepatitis Diagnosis, Prevention and Access to Care. November 27, 2012



S 1 8 4 5



The Geenius[™] protocol



2012 National Summit on HIV and Viral Hepatitis Diagnosis, Prevention and Access to Care. November 27, 2012



Geenius HIV-1/2 Interpretation Criteria

HIV-1 Positive = Any two of the four HIV-1 lines with at least one HIV-1 envelope (gp160 and/or gp41) line present

HIV-1 Indeterminate = Any HIV-1 line(s) that does not meet the requirements of HIV-1 positive

HIV-2 Positive = Both HIV-2 envelope lines (gp36 <u>and</u> gp140) present

HIV-2 Indeterminate = Only one HIV-2 envelope line (gp36 or gp140) present

HIV Negative = No test lines present

Valid assays = (HIV positive, HIV indeterminate and HIV negative) must have a control line present



Geenius HIV-1 and HIV-2 Result Categories

- HIV-1 Positive
- > HIV-1 Indeterminate
- HIV-2 Positive
- HIV-2 Positive with HIV-1 cross reactivity
- HIV-2 Indeterminate
- HIV Indeterminate
- > HIV Negative
- HIV Positive Untypable



The Geenius Software

		Non <th>C C C C C C C C C C C C C C C C C C C</th> <th>در ای ۵۵ ۵۵</th>	C C C C C C C C C C C C C C C C C C C	در ای ۵۵ ۵۵
		His Hold Hold Hold Hold Hold Hold Hold Hold	Diteria 1924 924 941	
=	BIO RAD Geenius Reader	eter fande fande forsen daten	- «•	
EHH I	Geenius Hear			

- ✓ No visual reading
- ✓ USB reader connection to Laptop computer containing Geenius Software
- ✓ Automated Reader calibration

- ✓ Automated reading and interpretation using proprietary algorithm
- ✓ Full traceability of sample ID and test ID
- ✓ Archiving of test results including a picture of each cassette

✓ LIS Connectivity

2012 National Summit on HIV and Viral Hepatitis Diagnosis, Prevention and Access to Care. November 27, 2012



Geenius HIV-1/2 Sensitivity (1)

- A total of 140 HIV-1 (Group M and O) known positive samples were tested on Geenius
 - ✓ 100% (95% CI, 97.2-100%) were found to be HIV-1 positive
- A total of 232 HIV-2 known positive samples from Africa, U.S. and Europe were tested on Geenius
 - ✓ 100% (95% CI, 98.4-100%) were found to be HIV-2 positive
 - ✓ 95% were classified as HIV-2 positive with HIV-1 crossreactivity
 - ✓ 5% demonstrated HIV-1 cross reactivity and were classified as HIV Untypable
- A total of 4 samples from patients infected with both HIV-1 and HIV-2 viruses were correctly classified as HIV-1positive and HIV-2 positive (HIV Untypable)



Geenius HIV-1/2 Sensitivity (2)

A total of 154 samples from 32 commercial HIV-1 seroconversion panels were tested on Geenius and the FDA licensed Bio-Rad HIV-1 Western blot assay

Geenius testing demonstrated greater sensitivity on 13 of the 32 (or 41%) seroconversion panels tested when compared to the Western blot assay

	GS HIV-1 Western Blot	Geenius HIV 1/2 Supplemental Assay
Negative	63	73
Indeterminate	42	16
HIV-1 Positive	49	65
Total	154	154



Geenius Specificity Testing

A total of 530 negative serum samples from blood bank and hospitals were tested with Geenius cassettes

530/530 or 100% specificity (95% CI 99.2-100%)

- (No false positive)
- 3.5 % were indeterminate for blood bank samples and 2% for patients samples
- Typically 15-25% of negative samples are HIV-1 Western blot indeterminate



2012 National Summit on HIV and Viral Hepatitis Diagnosis, Prevention and Access to Care. November 27, 2012

Geenius[™] HIV-1/2 Supplemental Assay A Complete Solution for HIV Confirmation & Differentiation



Summary and Conclusion

- ✓ Test Results in less than 30 minutes
- Automated reading and interpretation using proprietary algorithms
- ✓ Full traceability of sample ID and patient results
- ✓ 100% HIV-1 Sensitivity
- ✓ 100% HIV-2 Sensitivity with 90% HIV-2 differentiation
- ✓ 100% specificity
- ✓ CE marking pending
- ✓ FDA PMA approval planned
- ✓ CLIA Waiver (POC) approval planned



